Cell-Mediated Immunity Generated in Response to a Purified Inactivated Vaccine for Dengue Virus Type 1
ABSTRACT Dengue is the most prevalent arboviral disease afflicting humans, and a vaccine appears to be the most rational means of control. Dengue vaccine development is in a critical phase, with the first vaccine licensed in some countries where dengue is endemic but demonstrating insufficient effic...
Guardado en:
Autores principales: | Heather Friberg, Luis J. Martinez, Leyi Lin, Jason M. Blaylock, Rafael A. De La Barrera, Alan L. Rothman, J. Robert Putnak, Kenneth H. Eckels, Stephen J. Thomas, Richard G. Jarman, Jeffrey R. Currier |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
American Society for Microbiology
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9a70ddf949f2464fbfa4032091e25a8f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Targets and strategies for vaccine development against dengue viruses
por: Wen-Hung Wang, et al.
Publicado: (2021) -
Developing a Stabilizing Formulation of a Live Chimeric Dengue Virus Vaccine Dry Coated on a High-Density Microarray Patch
por: Jovin J. Y. Choo, et al.
Publicado: (2021) -
Avances en la investigación del virus dengue en Colombia: papel de los microARNs celulares en la respuesta anti-dengue virus
por: Castrillón-Betancur,Juan Camilo, et al.
Publicado: (2017) -
Regional Variation in Dengue Virus Serotypes in Sri Lanka and Its Clinical and Epidemiological Relevance
por: Tibutius T. P. Jayadas, et al.
Publicado: (2021) -
Dengue perinatal: Reporte de caso
por: Manzano Núñez,Ramiro, et al.
Publicado: (2017)